The University of Birmingham and Cure Leukaemia have combined to launch the “Birmingham, let’s cure leukaemia” campaign which aims to help the city find a cure for blood cancer in the next 30 years.
This collaboration will raise funds to support University of Birmingham researcher and co-founder of Cure Leukaemia, Professor Charlie Craddock and his teams based in the Centre for Clinical Haematology at the Queen Elizabeth Hospital and across the West Midlands, to continue their work to deliver ground-breaking new therapies to leukaemia patients across the region.
The aim by 2024 is to double the number of patients treated, double the capacity for clinical trials on offer, whilst looking to potentially leverage in excess of £100 million of free drugs for patients battling blood cancer. This will consolidate the Centre’s position as a world-leading centre for the treatment of blood cancer.
To help towards this aim, the University of Birmingham joined Cure Leukaemia in two of their major fundraising events:
The focus sees two leading forces in research and treatment of leukaemia joining together to encourage the local community, University staff, students and alumni (graduates of the University) to run and ride for Cure Leukaemia and the University of Birmingham and raise funds in aid of leukaemia research.
The combined fundraising initiative will directly help patients in the region like 18-year-old Brooke Evans from Redditch who has acute lymphoblastic leukaemia.
Brooke is receiving support and treatment for her disease as part of a clinical trial which is delivered through the clinical trials unit at the Centre for Clinical Haematology and the University of Birmingham.
She said, “there are more people in the same position as me and we need to make sure they have access to these treatments.”
With further fundraising, more patients like Brooke can be treated and with sustained funding, Birmingham can find a cure for leukaemia in the next 30 years.
Professor Charlie Craddock, the co-founder of Cure Leukaemia and Professor of Haemato-oncology at the University of Birmingham said,
“I am thrilled that the University of Birmingham and Cure Leukaemia are combining their efforts for the Great Birmingham Run and London 2 Paris: Inspiring the Revolution.
The University’s facilities, research and infrastructure are integral to all the work we do at the Centre for Clinical Haematology so their collaboration with Cure Leukaemia to help increase fundraising too is fantastic. It will allow us to continue to treat and save the lives of leukaemia patients all over the region, and help Birmingham find a cure for this terrible disease in the next 30 years.”
The West Midlands region, with a population of 5.5 million has the most ethnically diverse catchment area in Europe and, as a result, offers access to the broadest possible data pool for drug trials. Combined with a hub of leading medical research at the University of Birmingham, this makes Birmingham a centre of excellence in this field, offering hope to the 30,000 people who are diagnosed with blood cancer in the UK each year.
The Centre for Clinical Haematology is ideally sited near to the locations where joint patient care and collaborative research work is undertaken – close to the new Queen Elizabeth Hospital where the haematology and cancer wards are located and the University of Birmingham which hosts one of the largest Cancer Trials Units in the world.